You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
微芯生物(688321.SH):主要产品西达本胺续约进入国家医保目录
格隆汇 11-28 16:46

格隆汇11月28日丨微芯生物(688321.SH)公布,根据国家医保局、人力资源社会保障部印发的关于《国家基本医疗保险、工伤保险和生育保险药品目录》的通知(医保发[2019]46号),公司主要产品西达本胺续约进入国家医保目录。该产品具体情况如下:

药品名称:西达本胺

注册类别:化学药品第1.1类

药品分类:抗肿瘤药及免疫调节剂-其他抗肿瘤药物

医保分类:乙类

编号:71

剂型:口服常释剂型

独家品种:是

医保支付标准:343元(5mg/片)

功能主治:限既往至少接受过一次全身化疗的复发或难治的外周T细胞淋巴瘤(PTCL)患者

协议有效期:2020年1月1日至2021年12月31日

公司产品西达本胺已于2017年7月进入国家医保目录,本次续约进入国家医保目录将有利于该产品的销售,对公司的经营发展有积极的作用,预计短期不会对公司业绩产生重大影响。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account